Study #2018-0202
A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET;Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients with;Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-;0610 with and without Ruxolitinib in Patients with Myelofibrosis)
Study Status
Open
Treatment Agent
CPI-0610, Ruxolitinib
Principal Investigator
Prithviraj Bose
Description
The goal of this clinical research study is to learn if CPI-0610 alone or in combination with ruxolitinib can help to control myelofibrosis.
General Information
Disease Group: Malignant neoplasms stated as primary lymphoid haematopoietic
Treatment Agent: CPI-0610, Ruxolitinib
Treatment Location: Only at MD Anderson
Sponsor: Constellation Pharmaceuticals
Study Status
IRB Review and Approval Date: 07/11/2018
Recruitment Status: Open
Projected Accrual: 114
Resources and Links
Information and next steps
Disease:
Malignant neoplasms stated as primary lymphoid haematopoietic
Study phase:
Phase I/Phase II
Physician name:
Prithviraj Bose
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789